Irinotecan Hydrochloride Inj · 350 days since initial FDA posting
Brand: IRINOTECAN HYDROCHLORIDE
FDA lists Irinotecan Hydrochloride Inj as To Be Discontinued (Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)).
No availability text on this FDA row.
Irinotecan Hydrochloride Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Irinotecan Hydrochloride Injection
- Manufacturer
- Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
- Dosage Form
- Injection
- Presentation
- Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 25021-230-02)
- Package NDC
- 25021-230-02
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Sep 26, 2025
- Last Updated
- Sep 26, 2025
- Therapeutic Category
- Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals
Nearby, Other Irinotecan Shortage Records
Irinotecan Hydrochloride Injection
Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
Injection
Irinotecan Hydrochloride Injection
Teva Pharmaceuticals USA, Inc.
Injection
Irinotecan Hydrochloride Injection
Teva Pharmaceuticals USA, Inc.
Injection
Irinotecan Hydrochloride Injection
Ingenus Pharmaceuticals LLC
Injection
Irinotecan Hydrochloride Injection
Ingenus Pharmaceuticals LLC
Injection
FDA reason on file: Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals. General shortage guidance lives on the tracker hub.